

**IN THE UNITED STATES DISTRICT COURT
MIDDLE DISTRICT OF NORTH CAROLINA**

JOHN LAFFERTY,

Plaintiff,

vs.

Case No. 1:23-cv-574

BECTON, DICKINSON AND CO., et al.,

Defendants.

COMPLAINT

COMES NOW, Plaintiff, John Lafferty, by and through the undersigned counsel, and for his Complaint against Becton, Dickinson & Company, C.R. Bard, Inc.; Bard Access Systems, Inc.; and DOES 1 through 10 (collectively, the “Defendants”) states:

1. This is an action for damages relating to Defendants’ design, development, testing, assembling, manufacturing, packaging, promoting, marketing, distribution, supplying, and/or selling the defective device sold under the trade name of Bard PowerPort duo M.R.I. Implantable Port (hereinafter “PowerPort” or “Defective Device”).

2. Plaintiff, John Lafferty, is an adult citizen of Rockingham County, North Carolina, and claims damages as set forth below.

3. Defendant Becton, Dickinson and Company (“BD”) is a New Jersey corporation with a principal place of business at 1 Becton Drive in Franklin Lakes, New Jersey. BD is one of the largest global medical technology companies in the world with diverse business units offering products in various healthcare subfields. BD is engaged in the business of researching, developing, designing, licensing, manufacturing, distributing, supplying, selling, marketing and introducing into interstate commerce, either directly or indirectly through third parties or related entities, its medical devices, including the PowerPort. BD is the parent company of Defendants C.R. Bard, Inc. and Bard Access Systems, Inc.

4. Defendant C.R. Bard, Inc. (“Bard”) is a New Jersey corporation with its principal place of business located in 1 Becton Drive in Franklin Lakes, New Jersey. Bard conducts business throughout the United States, including the State of North Carolina, and is a wholly owned subsidiary of BD. Bard, as an agent of BD, is engaged in the business of researching, developing, designing, licensing, manufacturing, distributing, supplying, selling, marketing and introducing into interstate commerce, either directly or indirectly through third parties or related entities, its medical devices, including the PowerPort. Bard, along with its subsidiaries and business units, was acquired by BD in 2017 in a transaction which integrated and subsumed Bard’s business units into BD’s business units. In said transaction, Bard’s product offerings, including the PowerPort were taken over by and integrated into BD’s Interventional segment, one of three of BD’s principal business segments. Following the acquisition, Bard’s Board of Directors dissolved, with some former Bard directors joining BD’s Board of Directors.

5. Defendant Bard Access Systems, Inc. (“BAS”) is a Utah corporation with its principal place of business located in Salt Lake City, Utah. BAS conducts business throughout the United States, including the State of North Carolina, and is a wholly owned subsidiary of BD. BAS is engaged in the business of researching, developing, designing, licensing, manufacturing, distributing, supplying, selling, marketing and introducing into interstate commerce, either directly or indirectly through third parties or related entities, its medical devices, including the PowerPort.

6. BD is the nominal corporate parent of Bard and BAS, but the latter two are alter egos of BD in that BD exercises complete domination and control over Bard and BAS, having completely integrated the latter’s assets, liabilities, and operations into its own such that Bard and BAS have ceased to function as separate corporate entities.

7. BD's control over Bard and BAS has been purposefully used to perpetrate the violation of various legal duties in contravention of Plaintiff's legal rights.

8. The breaches by BD of various legal duties as described herein are the proximate cause of the injuries described herein.

9. In addition to BD's liability for Plaintiff's damages as a result of its abuse of the corporate form, BD is directly liable as a result of its own wrongful conduct as set forth herein.

10. Plaintiff is ignorant of the true names and capacities of defendants sued herein as DOES 1 through 10, inclusive, and therefore sues these defendants by such fictitious names. Plaintiff will amend this complaint to allege their true names and capacities when ascertained.

JURISDICTION AND VENUE

11. This Court has subject matter jurisdiction over the parties pursuant to 28 U.S.C. §1332(a) because the parties are citizens of different states and the amount in controversy exceeds \$75,000.00, exclusive of interest and cost.

12. Venue is proper in this Court pursuant to 28 U.S.C. §1391 by virtue of the facts that (a) a substantial part of the events or omissions giving rise to the claims occurred in this District and (b) Defendants' products are produced, sold to and consumed by individuals in the State of North Carolina, thereby subjecting Defendants to personal jurisdiction in this action and making them all "residents" of this judicial District.

13. Defendants have and continue to conduct substantial business in the State of North Carolina and in this District, distribute vascular access products in this District, receive substantial compensation and profits from sales of vascular access products in this district, and made material omissions and misrepresentations and breaches of warranties in this District, so as to subject them to *in personam* jurisdiction in this District.

14. Consistent with the Due Process Clause of the Fifth and Fourteenth Amendments, this Court has *in personam* jurisdiction over Defendants, because Defendants are present in the State of North Carolina, such that requiring an appearance does not offend traditional notions of fair and substantial justice.

PRODUCT BACKGROUND

15. The Bard PowerPort duo M.R.I. Implantable Port (“PowerPort”) is one of several varieties of port/catheter systems that has been designed, manufactured, marketed, and sold by Defendants.

16. According to Defendants, the PowerPort is a totally implantable vascular access device designed to provide repeated access to the vascular system for the delivery of medication, intravenous fluids, parenteral nutrition solutions, and blood products.

17. The intended purpose of the PowerPort is to make it easier to deliver medications directly into the patient’s bloodstream. The device is surgically placed completely under the skin and left implanted.

18. The PowerPort is a system consisting of two primary components: an injection port and a polyurethane catheter.

19. The injection port has a raised center, or “septum,” where the needle is inserted for delivery of the medication. The medication is carried from the port into the bloodstream through a small, flexible tube, called a catheter, that is inserted into a blood vessel.

20. The PowerPort is “indicated for patient therapies requiring repeated access to the vascular system. The port system can be used for infusion of medications, I.V. fluids, parenteral nutrition solutions, blood products, and for the withdrawal of blood samples.”

21. According to Defendants’ marketing materials, the polyurethane catheter “has less

propensity for surface biodegradation, making it more resistant to environmental stress cracking.”

22. The polyurethane comprising the catheter in the PowerPort is a formulation called Chronoflex AL, which Defendants obtain from a biomaterials supplier called AdvanSource Biomaterials Corporation (AdvanSource), which is a division of Mitsubishi Chemical America, Inc.

23. Chronoflex AL is one of a large number of biomaterials manufactured by AdvanSource, many of which have mechanical properties superior to Chronoflex AL.

24. The Chronoflex catheter included in Defendants’ PowerPort is comprised of a polymeric mixture of polyurethane and barium sulfate, a compound which is visible in certain radiologic studies.

25. Barium sulfate is known to contribute to reduction of the mechanical integrity of polyurethane *in vivo* as the particles of barium sulfate dissociate from the surface of the catheter over time, leaving microfractures and other alterations of the polymeric structure and degrading the mechanical properties of the catheter.

26. The mechanical integrity of a barium sulfate-impregnated polyurethane is affected by the concentration of barium sulfate as well as the homogeneity of the modified polymer.

27. Defendants’ manufacturing process in constructing the Chronoflex Catheter implanted in Plaintiff involved too high a concentration of barium sulfate particles, leading to improperly high viscosity of the raw polyurethane before polymerization and causing improper mixing of barium sulfate particles within the polymer matrix.

28. This improper mixing led to pockets of barium sulfate and entrapped air being distributed through the catheter body and on the inner and outer surfaces of same.

29. This defect in the manufacturing process led to a heterogeneous modified polymer which led to an irregular catheter surface replete with fissures, pits and cracks.

30. This irregular catheter surface leads to an increased risk of fracture, with the notches and irregularities on the surface acting as breaking points.

31. This unsafe condition and the resulting risk for fracture increases over time as barium sulfate loss from the catheter surface continues, a risk Defendants did not communicate to Plaintiff or his physicians.

32. Although the surface degradation and resulting risk of fracture can be reduced or avoided with design modifications to encapsulate the radiopaque compound or by using a different polymer formulation, Defendants elected not to incorporate those design elements into the PowerPort.

33. At all times relevant, Defendants misrepresented the safety of the PowerPort system, and negligently designed, manufactured, prepared, compounded, assembled, processed, labeled, marketed, distributed, and sold the PowerPort system as safe and effective device to be surgically implanted to provide repeated access to the vascular system for the delivery of medications, intravenous fluids, parenteral nutrition solutions, and blood products.

34. At all times relevant to this action, Defendants knew and had reason to know, that the PowerPort was not safe for the patients for whom they were prescribed and implanted, because once implanted the device was prone to fracturing, migrating, perforating internal vasculature, and otherwise malfunctioning.

35. At all times relevant to this action, Defendants knew and had reason to know that patients implanted with PowerPorts had an increased risk of suffering life threatening injuries, including, but not limited to: death; fracture; hemorrhage; thromboembolism; infection; cardiac

arrhythmia; severe and persistent pain; and perforations of tissue, vessels and organs, or the need for additional surgeries to remove the defective device.

36. Soon after the PowerPort was introduced to market, which was years before Plaintiff was implanted with his device, Defendants began receiving large numbers of adverse event reports (“AERs”) from health care providers reporting that the PowerPort was fracturing post-implantation and that fractured pieces were migrating throughout the human body, including to the heart and lungs. Defendants also received large numbers of AERs reporting that PowerPort was found to have perforated internal vasculature. These failures were often associated with reports of severe patient injuries such as:

- a. hemorrhage;
- b. cardiac/pericardial tamponade;
- c. cardiac arrhythmia and other symptoms similar to myocardial infarction;
- d. severe and persistent pain;
- e. and perforations of tissue, vessels and organs; and
- f. upon information and belief, even death.

37. In addition to the large number of AERs which were known to Defendants and reflected in publicly accessible databases, there are thousands of recorded device failures and/or injuries related to the Defendants’ implantable port products – including the product implanted in Plaintiff – which were concealed from medical professionals and patients through submission to the FDA’s controversial Alternative Summary Reporting (“ASR”) program.

38. The FDA halted the ASR program after its existence was exposed by a multi-part investigative piece, prompting a widespread outcry from medical professionals and patient

advocacy groups.¹

39. Prior to the discontinuation of the ASR program, Defendants reported thousands of episodes of failures of their implanted port/catheter products – including numerous episodes of catheter fracture under the ASR exemption, thereby concealing them from physicians and patients.

40. Defendants were aware or should have been aware that the PowerPort had a substantially higher failure rate than other similar products on the market, yet Defendants failed to warn consumers of this fact.

41. Defendants also intentionally concealed the severity of complications caused by the PowerPort and the likelihood of these events occurring.

42. Rather than alter the design of the PowerPort to make it safer or adequately warn physicians of the dangers associated with the PowerPort, Defendants continued to actively and aggressively market the PowerPort as safe, despite their knowledge of numerous reports of fractures and associated injuries.

43. Moreover, Defendants’ warnings suggested that fracture of the device could only occur if the physician incorrectly placed the device such that “compression or pinch-off” was allowed to occur. In reality, however, Defendants knew internally these devices were fracturing and causing serious injuries due to defects in the design, manufacturing and lack of adequate warnings.

44. The conduct of Defendants, as alleged in this Complaint, constitutes willful, wanton, gross, and outrageous corporate conduct that demonstrates a conscious disregard for the safety of Plaintiff. Defendants had actual knowledge of the dangers presented by the PowerPort System,

¹ Christina Jewett, Hidden Harm: Hidden FDA Reports Detail Harm Caused by Scores of Medical Devices, Kaiser Health News (Mar. 2019)

yet consciously failed to act reasonably to:

- a. Adequately inform or warn Plaintiff, his prescribing physicians, or the public at large of these dangers;
- b. Establish and maintain an adequate quality and post-market surveillance system;
or
- c. Recall the PowerPort System from the market.

SPECIFIC FACTUAL ALLEGATIONS AS TO PLAINTIFF

45. On or about February 22, 2022, Plaintiff was implanted with a PowerPort via right internal jugular vein, for administration of chemotherapy to treat colon cancer. This procedure took place at Atrium Health Wake Forest Baptist Medical Center in Winston-Salem, Forsyth County, North Carolina.

46. Defendant, BAS directly or through their agents, apparent agents, servants or employees designed, manufactured, marketed, advertised, distributed and sold the PowerPort that was implanted in Plaintiff.

47. On or about April 12, 2022, Plaintiff underwent one of his chemotherapy sessions in which Oxaliplatin, a chemotherapy drug, was infused through the PowerPort into Plaintiff's bloodstream. About halfway through the session, Plaintiff began experiencing pain, burning, and swelling above the PowerPort site.

48. Plaintiff immediately underwent a port check. The port check revealed the PowerPort had ruptured and had been leaking chemotherapy medication into Plaintiff's body.

49. Medical personnel were unable to remove the defective device when the rupture was discovered due to a medication Plaintiff was given that same day. Plaintiff ultimately had to wait approximately a month to have the ruptured device removed.

50. On or about May 10, 2022, Plaintiff was admitted to Atrium Health Wake Forest

Baptist Medical Center for removal and replacement of the defective PowerPort.

51. Due to the defective device, Plaintiff suffered damages and continues to suffer damages, including, but not limited to, undergoing an unnecessary major surgery, pain and suffering, increased risk of future severe and permanent injuries, severe emotional distress, and ongoing fear and anxiety from future injuries, including but not limited to, cardiac tamponade.

52. The Defendants concealed—and continue to conceal—their knowledge of PowerPort’s unreasonably dangerous risks from Plaintiff and his physicians.

53. Numerous reports of PowerPort catheter-related fracture in the absence of medical provider error were recorded and reported to Defendants prior to the implantation of the PowerPort in Plaintiff.

54. However, Defendants continued to actively and aggressively market the PowerPort as safe, despite knowledge of numerous reports of such injuries. Defendants utilized marketing communications, including the Instruction for Use, and direct communications from sales representatives to Plaintiff’s health care providers to intentionally mislead his health care providers into believing these failures were caused by factors other than catheter design and composition, such as physician failure.

55. Defendants did not adequately warn Plaintiff or Plaintiff’s physicians of the true quantitative or qualitative risk of fracture and migration or dislodgement associated with the PowerPort.

56. Defendants did not adequately warn that the scope of catheter fracture extends beyond cases of pinch-off syndrome to Plaintiff or his physicians.

57. Defendants did not adequately communicate the extent or seriousness of the danger of catheter fracture to Plaintiff or his physicians.

58. Rather than alter the design of their product to make it safer or warn physicians of the dangers associated with the PowerPort, the Defendants chose to continue their efforts to promote their defective product.

59. Plaintiff's physicians relied upon the representations, including the instructions for use distributed with the product implanted in Plaintiff, and advertisements to Plaintiff's detriment.

60. The Defendants knowingly concealed the dangerous propensity of this device to fracture and/or dislodge and cause foreign materials to be introduced into the Plaintiff's bloodstream. Defendants further concealed their knowledge that these failures were occurring other than by doctors causing pinch-off through placement, and that the failures were known to be causing serious injuries.

61. As a result of the failure of the Defendants' PowerPort and the Defendants' wrongful conduct in designing, manufacturing, and marketing this defective product, Plaintiff and Plaintiff's physician were unaware, and could not have reasonably known or have learned through reasonable diligence, that Plaintiff had been exposed to the risks identified in this Complaint, and that those risks were the direct and proximate result of the Defendants' acts, omissions and misrepresentations.

62. The Defendants failed to conduct adequate and sufficient post-marketing surveillance after they began marketing, advertising, distributing and selling the PowerPort.

63. As a result of the Defendants' actions and inactions, Plaintiff was injured due to the use of the PowerPort, which has caused and will continue to cause Plaintiff's various physical, mental, and emotional injuries and damages. Accordingly, Plaintiff seeks compensatory damages.

COUNT I – NEGLIGENCE – ALL DEFENDANTS

64. Plaintiff incorporates the preceding paragraphs as if set out fully herein.

65. Plaintiff brings this count against Defendants BD, Bard, BAS, and Does 1 through 10, inclusive.

66. The Defendants owed Plaintiff a duty to exercise reasonable care when designing, manufacturing, marketing, advertising, distributing, selling and conducting post-market surveillance of the PowerPort.

67. The Defendants failed to exercise due care under the circumstances and therefore breached this duty by:

- a. Failing to properly and thoroughly test the PowerPort before releasing the device to market, and/or failing to implement feasible safety improvements;
- b. Failing to properly and thoroughly analyze the data resulting from any pre-market testing of the PowerPort;
- c. Failing to conduct sufficient post-market testing and surveillance of the PowerPort;
- d. Designing, manufacturing, marketing, advertising, distributing, and selling the PowerPort to consumers, including Plaintiff, without an adequate warning of the significant and dangerous risks of the PowerPort and without proper instructions to avoid the harm which could foreseeably occur as a result of using the device;
- e. Failing to exercise due care when advertising and promoting the PowerPort; and
- f. Negligently continuing to manufacture, market, advertise, and distribute the PowerPort after Defendants knew or should have known of its adverse effects.

68. As a direct and proximate result of the Defendants' actions, omissions and

misrepresentations, Plaintiff has suffered, and will continue to suffer, severe physical pain and injuries which are permanent and lasting in nature, emotional distress, loss of the capacity for the enjoyment of life, medical expenses, and economic loss as alleged herein. These damages have occurred in the past and will continue into the future.

69. In performing the foregoing acts, omissions, and misrepresentations, Defendants acted grossly negligent, fraudulently, and with malice so as to justify an award of punitive and/or exemplary damages.

COUNT II – FAILURE TO WARN – ALL DEFENDANTS

70. Plaintiff incorporates the preceding paragraphs as if set out fully herein.

71. Plaintiff brings this count against Defendants BD, Bard, BAS, and Does 1 through 10, inclusive.

72. Defendants designed, set specifications, manufactured, prepared, compounded, assembled, processed, marketed, labeled, distributed, and sold the PowerPort, including the one implanted into Plaintiff, into the stream of commerce and in the course of same, directly advertised and marketed the device to consumers or persons responsible for consumers, and therefore had a duty to warn of the risk of harm associated with the use of the device and to provide adequate instructions on the safe and proper use of the device.

73. At the time Defendants designed, manufactured, prepared, compounded, assembled, processed, marketed, labeled, distributed, and sold the device into the stream of commerce, the device was defective and presented a substantial danger to users of the product when put to its intended and reasonably anticipated use, namely as an implanted port/catheter system to administer medications. Defendants failed to adequately warn of the device's known or reasonably scientifically knowable dangerous propensities, and further failed to adequately

provide instructions on the safe and proper use of the device.

74. Defendants knew or should have known at the time they manufactured, labeled, distributed and sold the PowerPort that was implanted into Plaintiff that the PowerPort posed a significant and higher risk of fracture and resulting serious injuries than other similar devices.

75. Defendants further knew that these devices were fracturing and migrating or dislodging for reasons other than “pinch-off” caused by the physician’s initial placement of the device.

76. As a result, the devices were unreasonably dangerous and posed a significant risk of harm to a reasonably foreseeable claimant when put to a reasonably anticipated use in that the devices were dangerous to an extent beyond that which would be contemplated by the ordinary consumer who purchases it.

77. Defendants failed to timely and reasonably warn of material facts regarding the safety and efficacy of the PowerPort in that Defendants failed to provide any warning that these devices could fracture and migrate for reasons other than “pinch-off” caused by the physician’s initial placement of the device, as described herein.

78. No reasonable health care provider, including Plaintiff’s health care providers, and no reasonable patient would have used the device in the manner directed, had those facts been made known to the prescribing healthcare providers or the consumers of the device.

79. Had the Defendants provided an adequate warning of the risks attendant to the PowerPort enumerated herein, Plaintiff would not have consented to be implanted with the product.

80. The warnings, labels, and instructions provided by the Defendants at all time relevant to this action, are and were inaccurate, intentionally misleading, and misinformed and

misrepresented the risks and benefits and lack of safety and efficacy associated with the device.

81. The health risks associated with the device as described herein are of such a nature that ordinary consumers would not have readily recognized the potential harm.

82. The device, which was designed, manufactured, prepared, compounded, assembled, processed, marketed, labeled, distributed, and sold into the stream of commerce by Defendants, was defective at the time of release into the stream of commerce due to inadequate warnings, labeling and/or instructions accompanying the product.

83. When Plaintiff was implanted with the device, Defendants failed to provide adequate warnings, instructions, or labels regarding the severity and extent of health risks posed by the device, as discussed herein.

84. Defendants intentionally underreported the number and nature of adverse events associated with fracture of the devices to Plaintiff's health care providers, as well as the FDA.

85. Neither Plaintiff nor his health care providers knew of the substantial danger associated with the intended and foreseeable use of the device as described herein.

86. Plaintiff and his health care providers used PowerPort in a normal, customary, intended, and foreseeable manner, namely as a surgically placed device used to make it easier to deliver medications directly into the patient's bloodstream. Moreover, Plaintiff's health care providers did not place or maintain the device incorrectly such that it caused the device to "pinch-off" or increased the risk of malfunction.

87. Upon information and belief, the defective and dangerous condition of the device, including the one implanted into Plaintiff, existed at the time they were manufactured, prepared, compounded, assembled, processed, marketed, labeled, distributed, and sold by Defendants to distributors and/or healthcare professionals or organizations. Upon information and belief, the

device implanted in Plaintiff was in the same condition as when it was manufactured, inspected, marketed, labeled, promoted, distributed and sold by Defendants.

88. Defendants' lack of sufficient warning and/or instructions was the direct and proximate cause of Plaintiff's serious physical injuries, pain and suffering, and economic damages in an amount to be determined at trial. In other words, had Defendants provided adequate warnings, Plaintiff and his physicians would not have used the device.

COUNT III – DEFECTIVE DESIGN – ALL DEFENDANTS

89. Plaintiff incorporates the preceding paragraphs as if set out fully herein.

90. Plaintiff brings this count against Defendants BD, Bard, BAS, and Does 1 through 10, inclusive.

91. The PowerPort was unreasonably dangerous to the user or consumer for its intended use and was more dangerous than a reasonably prudent user and consumer would expect when used in an intended or reasonably foreseeable manner, as detailed above.

92. The PowerPort was in a defective condition at the time that it left the possession or control of Defendants as a result of the negligence of Defendants, as detailed above.

93. Defendants knew or reasonably should have known that the PowerPort, as designed, tested, packaged, labeled and sold was defective and unreasonably dangerous for its intended use.

94. The PowerPort was expected to and did reach the consumer without substantial change in its condition.

95. Defendants placed the PowerPort into the stream of commerce in such a condition in completed disregard for the safety of the public.

96. Defendants knew or should have known that physicians and other healthcare

providers began using the PowerPort to administer medications in the setting of chemotherapy patients, such as Plaintiff, despite its substantially higher risk of fracture and migration or dislodgement and resulting serious injuries than other similar devices, as further described herein.

97. At all relevant times, there existed a safer, feasible alternative design which would have reduced or eliminated the risks that led to the Plaintiff's injuries.

98. As a direct and proximate result of the PowerPort's aforementioned defects and Defendants' wrongful acts and/or omissions, Plaintiff was injured, was forced to undergo surgical removal of the PowerPort, and caused and/or will in the future be caused to endure pain and suffering, severe emotional distress, financial or economic loss, including, but not limited to, obligations for medical services and expenses, and other damages.

COUNT IV – FRAUDULENT CONCEALMENT – ALL DEFENDANTS

99. Plaintiff incorporates the preceding paragraphs as if set out fully herein.

100. Plaintiff brings this count against Defendants BD, Bard, BAS, and Does 1 through 10, inclusive.

101. Beginning from the time Defendants introduced the devices to the marketplace and continuing to present, Defendants fraudulently concealed information with respect to the PowerPort in the following particulars:

- a. Defendants represented through the labeling, advertising, marketing materials, seminar presentations, publications, notice letters, and regulatory submissions that the PowerPort was safe and fraudulently withheld and concealed information about the substantial risks of using the PowerPort;
- b. Defendants represented that the PowerPort was safer than other alternative

systems and fraudulently concealed information which demonstrated that the PowerPort was not safer than alternatives available on the market;

- c. Defendants concealed that it knew these devices were fracturing and migrating from causes other than the manner in which the implanting physician implanted the device; and
- d. That frequency of these failures and the severity of injuries were substantially worse than had been reported.

102. The Defendants had sole access to material facts concerning the dangers and unreasonable risks of the PowerPort.

103. The concealment of information by the Defendants about the risks of the PowerPort was intentional, and the representations made by Defendants were known by Defendants to be false.

104. The concealment of information and the misrepresentations about the PowerPort was made by the Defendants with the intent that Plaintiff's health care providers and Plaintiff rely upon them.

105. Plaintiff and his physicians relied upon the representations and were unaware of the substantial risks of the PowerPort which the Defendants concealed from the public, including Plaintiff and his physicians.

106. As a direct and proximate result of the Defendants' actions, omissions and misrepresentations, Plaintiff has suffered, and will continue to suffer, severe physical pain and injuries which are permanent and lasting in nature, emotional distress, loss of the capacity for the enjoyment of life, medical and nursing expenses, surgical expenses, and economic loss as alleged herein. These damages have occurred in the past and will continue into the future.

107. The Defendants acted with oppression, fraud, and malice towards Plaintiff, who accordingly requests that the trier of fact, in the exercise of its sound discretion, award additional damages for the sake of example and for the purpose of punishing Defendants for their conduct, in an amount sufficiently large to be an example to others, and to deter this Defendants and others from engaging in similar conduct in the future.

108. Had Defendants not concealed this information, neither Plaintiff's nor his health care providers would have consented to using the device in Plaintiff.

**COUNT V – NORTH CAROLINA UNFAIR AND DECEPTIVE
TRADE PRACTICES ACT – ALL DEFENDANTS**

109. Plaintiff incorporates the preceding paragraphs as if set out fully herein.

110. Plaintiff brings this count against Defendants BD, Bard, BAS, and Does 1 through 10, inclusive.

111. The acts and practices engaged in by Defendants constitute unlawful, unfair, and/or deceptive business or trade practices in violation of the North Carolina Unfair and Deceptive Trade Practices Act, N.C. Gen. Stat. § 75-1.1, *et seq.* (the “UDTPA”).

112. Defendants engaged in unlawful practices, including deception, false promises, misrepresentation, and/or the concealment, suppression, or omission of material facts in connection with the sale, distribution, and/or advertisement of the PowerPort product in violation of the UDTPA.

113. Defendants further engaged in unfair, unconscionable, deceptive, deliberately misleading, false, and/or deceptive acts and practices, all in violation of the UDTPA, and as further described herein, which created a likelihood of confusion or misunderstanding on Plaintiff's part with respect to the PowerPort product he purchased, including, but not limited to, misrepresenting that the PowerPort was reasonably safe for use and failing to adequately disclose

the substantial risk of fracture and harm the product entailed given the large number of adverse events Defendants knew or should have been aware of but did not adequately disclose to Plaintiff.

114. Defendants' conduct was in or affecting commerce, namely, Defendants sold and Plaintiff purchased the PowerPort, a product that Defendants falsely represented as having certain characteristics and benefits it did not have, *inter alia*, that it was reasonably safe for use, as further set forth above, in violation of the UDTPA.

115. Defendants engaged in such conduct knowing it was in an inequitable position over Plaintiff, having all the information about its product and access to such adverse event reports, while Plaintiff did not.

116. Defendants' conduct and practices engaged in offends established public policy and is unethical and substantially injurious to consumers such as Plaintiff.

117. As a result of Defendants' conduct, Plaintiff suffered economic and actual damages in that the product he purchased was misrepresented and worth far less than the product he thought he had purchased, had Defendants' representations been true.

118. Defendants' actions and omissions constitute fraudulent, willful, knowing, and intentional conduct. In doing so, Defendants misled Plaintiff, and his physicians, to believe that the PowerPort was reasonably safe for use.

119. As a result of Defendants' deceptive practices, Defendants caused injury to Plaintiff, as further described herein, including having to undergo an unnecessary procedure during the course of his chemotherapy treatment to remove the defective, ruptured device.

PUNITIVE DAMAGES

120. Plaintiffs are entitled to an award of punitive and exemplary damages based upon

Defendants' intentional, willful, knowing, fraudulent, malicious acts, omissions, and conduct, and their complete and total reckless disregard for the public safety and welfare. Defendants intentionally and fraudulently misrepresented facts and information to both the healthcare community and the general public, including Plaintiff and his health care providers, by making intentionally false and fraudulent misrepresentations about the safety and efficacy of the PowerPort. Defendants intentionally concealed the true facts and information regarding the serious risks of harm associated with the implantation of said product, and intentionally downplayed the type, nature, and extent of the adverse side effects of being implanted with the device, despite Defendants' knowledge and awareness of the serious and permanent side effects and risks associated with use of same. Defendants further intentionally sought to mislead health care providers and patients, including Plaintiff and his health care providers, regarding the cause of dislodgement and migration failures of the device.

121. Defendants had knowledge of, and were in possession of evidence demonstrating that, the PowerPort caused serious physical side effects. Defendants continued to market said product by providing false and misleading information with regard to the product's safety and efficacy to the regulatory agencies, the medical community, and consumers of the device, notwithstanding Defendants' knowledge of the true serious side effects of the PowerPort, Defendants failed to provide accurate information and warnings to the healthcare community that would have dissuaded physicians from surgically implanting the PowerPort and consumers from agreeing to being implanted with the PowerPort, thus depriving physicians and consumers from weighing the true risks against the benefits of prescribing and implanting the PowerPort.

122. As a direct, proximate, and legal result of Defendants' acts and omissions as described herein, and Plaintiff's implantation with Defendants' defective product, Plaintiff

suffered, and will continue to suffer, the injuries and damages described in this complaint.

WHEREFORE, Plaintiffs demands judgment against Defendants for compensatory, special, and punitive damages, together with interest, costs of suit, attorneys' fees, and all such other relief as the Court deems just and proper.

PRAYER

WHEREFORE, Plaintiff prays for judgment against each of the Defendants as follows:

- a. Judgment be entered against all Defendant on all causes of action of this Complaint;
- b. Plaintiff be awarded his full, fair, and complete recovery for all claims and causes of action relevant to this action;
- c. Plaintiff be awarded general damages according to proof at the time of trial;
- d. Plaintiff be awarded damages, including past, present, and future, medical expenses according to proof at the time of trial;
- e. Plaintiff be awarded costs, attorney's fees, and treble damages for engaging in unfair and deceptive practices in connection with Plaintiff's claims under the North Carolina Unfair and Deceptive Trade Practices Act, N.C. Gen. Stat. § 75-1.1, (UDTPA), and N.C. Gen. Stat. §§ 75-16, 75-16.1.
- f. Plaintiff be awarded punitive damages according to proof at the time of trial;
- g. Awarding pre-judgment and post-judgment interest to the Plaintiff;
- h. Awarding the costs and the expenses of this litigation to the Plaintiff.
- i. For such other and further relief as the court may deem just and proper.

DEMAND FOR JURY TRIAL

Plaintiff hereby demands trial by jury on all issues.

Respectfully submitted,

/s/ Brian L. Kinsley

Brian L. Kinsley, Esq.

blkinsley@crlegalteam.com

CR Legal Team, LLP

2400 Freeman Mill Road, Ste. 200

Greensboro, NC 27406

Phone: 336-333-9899

Fax: 336-333-9894

N.C. State Bar No. 38683

ATTORNEY FOR PLAINTIFF